Novartis Secures EU Approval for Rhapsido: A New O...
Category : Approval/Launch 28 April 2026The treatment landscape for chronic spontaneous urticaria (CSU) just shifted. Novartis has secured E...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
AbbVie Files for Subcutaneous Induction of SKYRIZI...
Category : Clinical Trial Update 28 April 2026AbbVie has submitted a new application to the U.S. Food and Drug Administration seeking approval for...
Johnson & Johnson’s IMAAVY Secures FDA Priority Re...
Category : Approval/Launch 28 April 2026Johnson & Johnson has received Priority Review designation from the U.S. Food and Drug Administr...
Thryv Therapeutics Advances THRV-1268 in Long QT S...
Category : ODD/BTA/FTA Status 27 April 2026Fast Track status + Phase 2/3 dosing marks a critical inflection point. A small biotech just made a...
Addex & Neurosterix Push NTX-253 Toward Phase 1 Re...
Category : Clinical Trial Update 27 April 2026A quiet but important milestone is approaching in CNS drug development. Addex Therapeutics announced...
Latest Newsletter Post
-
Johnson & Johnson’s IMAAVY Secures..
28 April 2026
-
AbbVie Files for Subcutaneous Induc..
28 April 2026
-
Novartis Secures EU Approval for Rh..
28 April 2026
-
GE HealthCare Advances a Potential..
27 April 2026
-
Addex & Neurosterix Push NTX-253 To..
27 April 2026
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com